Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

Phase I Study of Novel Drug Shows Preliminary Activity in Mesothelin-Expressing Tumors

Anetumab ravtansine was well tolerated and there was "a positive trend" suggesting that high mesothelin expression may indicate which cancer patients benefit from BAY 94-9343.

Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors

Premium

The company is testing out its immune-stimulating antibody conjugate platform technology, hitching its proprietary molecule to trastuzumab.

Tolero Pharmaceuticals Drug Added to Beat AML Umbrella Trial

Tolero's investigational agent dubermatinib will be evaluated in AML patients who harbor a TP53 mutation and/or a complex karyotype.

BeiGene's Lifirafenib Shows Preliminary Activity in Patients with Molecularly Defined Tumors

In a study published in the Journal of Clinical Oncology, partial responses were observed in patients with BRAF V600-mutated and KRAS-mutated solid tumors.

AnHeart to Launch Phase II Taletrectinib Trials in Molecularly Defined Cancers

The Chinese drug evaluation agency has granted the investigational new drug clinical trial authorization to taletrectinib in NRTK- and ROS1-mutated cancer patients.

Mar 18, 2020

IDEAYA, Pfizer to Evaluate Drug Combination in Solid Tumors with GNAQ or GNA11 Hotspot Mutations

Mar 17, 2020

InxMed Doses First Patient in Phase IB Trial of FAK Inhibitor for NRAS-Mutated Melanoma

Mar 16, 2020

Five Prime Therapeutics Reports Bemarituzumab Shrunk Gastric Tumors in Phase I Trial

Mar 12, 2020

QED Therapeutics Doses First FGFR-Mutated Patients in Phase II, Phase III Clinical Trials

Mar 09, 2020

Revolution Medicines SHP2 Inhibitor Enters Netherlands Cancer Institute-Sponsored Phase I/IB Trial

Mar 09, 2020

Black Diamond Therapeutics Targeting EGFR, HER-Mutated Cancers in Phase I/II Studies

Premium
Mar 05, 2020

Trovagene Exploring PLK1 Inhibitor in Various Biomarker-Defined Cancer Indications

Premium
Feb 27, 2020

MapKure, BeiGene, SpringWorks to Start Phase I Trial of BRAF Inhibitor in Solid Tumors

Feb 26, 2020

iOnctura Doses First Patient in Phase I Study of Novel PI3K Inhibitor for Solid Tumors

Feb 18, 2020

Exosome-Based Treatment Targeting KRAS G12D-Mutated Pancreatic Cancer to Enter Human Studies Next Month

Premium
Feb 14, 2020

Epizyme's New Drug Application for Tazemetostat Accepted by FDA

Feb 11, 2020

Novartis' New Drug Application for MET Inhibitor Capmatinib Accepted by FDA

Feb 11, 2020

Advaxis Taps Personalis for Biomarker Discovery in Lung Cancer Immunotherapy Program

Feb 05, 2020

Genprex to Focus on Developing Immunogene Therapy, Start Lung Cancer Trials This Year

Jan 31, 2020

Cytovia's CAR NK Alliance With NYSCF, UCSF Aims to Overcome Negative Side Effects of CAR T Drugs

Premium
Jan 31, 2020

CytoDyn Seeking to Expand Enrollment in Study Based on Promising Leronlimab Data

Jan 30, 2020

FDA Accepts Tempest Therapeutics' IND for TPST-1495

Jan 29, 2020

Geneos Therapeutics' Personalized Vaccine to be Evaluated in Clinical Trial for Liver Cancer

Jan 27, 2020

National Brain Tumor Society Backs Oncoceutics' Phase II Trial for Subset of High-Grade Gliomas

Jan 21, 2020

FDA Accepts Bridge Biotherapeutics' Investigational New Drug Application for Lung Cancer Drug

More articles

What's Popular?

In Drug Discovery & Development

  1. Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors

    Premium

  2. Phase I Study of Novel Drug Shows Preliminary Activity in Mesothelin-Expressing Tumors

  3. Tolero Pharmaceuticals Drug Added to Beat AML Umbrella Trial

  4. BeiGene's Lifirafenib Shows Preliminary Activity in Patients with Molecularly Defined Tumors

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.